Dipeptidyl Peptidase 4

• 

  Subject Areas on Research

  • Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. 
  • CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. 
  • Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. 
  • Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. 
  • Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. 
  • Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. 
  • Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition. 
  • Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV. 
  • Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. 
  • Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. 
  • Expression of renal cell protein markers is dependent on initial mechanical culture conditions. 
  • Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways. 
  • Gut peptides in the treatment of diabetes mellitus. 
  • In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • Novel genetic loci associated with hippocampal volume. 
  • Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. 
  • Preclinical developments in type 2 diabetes. 
  • Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats. 
  • Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. 
  • Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients. 
  • Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4. 
  • The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. 
  • The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. 
  • Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.